New research at Flinders is focused on finding more effective treatment options for people with three aggressive forms of blood cancer.
Acute myeloid leukemia, multiple myeloma and diffuse large B-cell lymphoma are among the most devastating of the blood cancers.
Despite significant advances in therapy, relapse and resistance to medication is common among patients with these diseases.
Dr Giles Best has received a Flinders Foundation Health Seed Grant to determine the efficacy of a new drug, TR-57, against acute myeloid leukemia, multiple myeloma and diffuse large B-cell lymphoma cells.
“Our preliminary data on these diseases suggests that TR-57 may represent an effective therapy, as a single agent or in combination with other drugs that are in current use or clinical trials,” Dr Best said.
“The data generated from this project, with support from Flinders Foundation, will determine how effective TR-57 may be as a new treatment for these aggressive malignancies and identify the particular subgroups of patients that are likely to benefit the most from treatment with this novel compound.”
Research category: Biomedical
Project title: TR-57 as a novel therapeutic agent for acute myeloid leukemia, multiple myeloma and diffuse large B-cell lymphoma
Lead researcher: Dr Giles Best
Flinders Foundation acknowledges the Kaurna people as the traditional custodians of the land on which the Flinders precinct was established. We acknowledge the Kaurna people’s deep and ongoing connection to land, waters and community, and pay our respect to their Elders, past and present.